Metropolis Healthcare · NSE: METROPOLIS · BSE: 542650
Q4 FY22 results · Jan–Mar 2022
Metropolis Healthcare reported revenue from operations of ₹305.90 crore (up 4.9% from Q4 FY21) and net profit of ₹40.15 crore (down 34.5% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 305.90 | 291.73 | +4.9% | 293.05 | +4.4% |
| Other income | 5.68 | 2.07 | +174.9% | 2.61 | +117.5% |
| Total income | 311.58 | 293.80 | +6.1% | 295.66 | +5.4% |
| Profit before tax | 56.47 | 81.65 | −30.8% | 56.09 | +0.7% |
| Net profit for the period | 40.15 | 61.32 | −34.5% | 41.22 | −2.6% |
| Attributable to shareholders of the company | 39.99 | 61.35 | −34.8% | 41.04 | −2.6% |
| EPS, basic (₹) | 7.81 | 12.05 | −35.2% | 8.02 | −2.7% |
| Net margin (%) | 13.1 | 21.0 | 14.1 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 261.05 | 238.36 | +9.5% | 212.24 | +23.0% |
| Other income | 5.73 | 42.08 | −86.4% | 1.45 | +296.1% |
| Total income | 266.78 | 280.44 | −4.9% | 213.68 | +24.8% |
| Profit before tax | 46.29 | 109.39 | −57.7% | 33.46 | +38.4% |
| Net profit for the period | 33.08 | 94.30 | −64.9% | 24.86 | +33.1% |
| EPS, basic (₹) | 6.47 | 18.50 | −65.0% | 4.86 | +33.1% |
| Net margin (%) | 12.7 | 39.6 | 11.7 |
Consolidated
- Filed with BSE
- 25 May 2022, 18:21 IST
- Board meeting
- 24 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 May 2022, 18:21 IST
- Board meeting
- 18 Jul 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE